Scientific Presentations

May 2026

ISPOR 2026: Charactering Patients with Fibromyalgia: A U.S. Real-World Claims Analysis

May 2026

2nd Richard Slayman Clinical Xenotransplantation Workshop

TNX-1500: The History and Promise of α-CD154 Monoclonal Antibody Immunomodulation for Xenotransplantation

May 2026

Global Lyme Alliance Symposium

TNX-4800: A Long-Acting, Bactericidal, Human Monoclonal Antibody to Prevent Lyme Disease in the U.S.

May 2026

AAPA 2026

Treatment with TNX-102 SL (CBP SL) Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia

Pharmacokinetic Characterization of Tonmya^® (TNX-102 SL), a Sublingual Formulation of Cyclobenzaprine (CBP SL) for the Treatment of Adults with Fibromyalgia

Tonmya^® (TNX-102 SL; CBP SL) Steady-State Pharmacokinetics Compared to Oral Simulations

April 2026

4th Annual Ticks and Tickborne Diseases Symposium: TNX-4800 Phase 1 Data and Plans for Adaptive Phase 2 Field Study

April 2026

American Association for Cancer Research (AACR) Annual Meeting 2026: In Vitro Characterization of Fully Human Antagonistic Anti-BTLA Monoclonal Antibodies

April 2026

American Association for Cancer Research (AACR) Annual Meeting 2026: Pharmacokinetics of TNX-1700 in Non-Human Primates and Human FcRn/Serum Albumin Transgenic Mice

March 2026

World Vaccine Conference 2026 — A Long-Acting Monoclonal Antibody for Prevention of Lyme Disease

Mark S. Klempner, MD, UMass Chan Medical School

March 2026

8th International Congress on Controversies in Fibromyalgia Oral Presentations

March 2026

2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting

January 2026

Non-Opioid Pain Therapeutics Summit, Boston MA / 27-29 Jan 2026

October 2025

American College of Rheumatology Convergence Conference 2025, Chicago: TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Participants With Fibromyalgia

October 2025

World Vaccine Conference 2025, Amsterdam: Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine

October 2025

61st Annual Congress of the Japan Society for Transplantation

September 2025

PainWeek 2025 — Randomized, double-blind, placebo-controlled confirmatory Phase 3 trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in fibromyalgia

September 2025

PainWeek 2025 — Sublingual cyclobenzaprine (TNX-102 SL) for fibromyalgia: efficacy and safety in two randomized placebo-controlled trials

September 2025

PainWeek 2025 — TNX-102 SL, cyclobenzaprine HCl sublingual tablets, demonstrates pain reduction and favorable tolerability in patients with fibromyalgia

September 2025

PainWeek 2025 — Steady-state pharmacokinetic properties of a sublingual formulation of cyclobenzaprine (CBP) HCl (TNX-102 SL): comparison to simulations of oral immediate-release CBP

July 2025

World Congress on Vaccines 2025 — TNX-801, a Single-Dose Live Vaccine Platform for Mpox and Other Emerging Viral Diseases: Safety, Immunogenicity, and Efficacy

June 2025

EULAR 2025: Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Targets Nonrestorative Sleep and Provides Sustained Pain Reduction

April 2025

AACR 2025: TFF2-mediated CXCR4 partial agonism outperforms CXCR4 antagonism in reducing murine gastric cancer by suppressing PMN-MDSC generation

April 2025

AAPM PainConnect 2025: Sublingual Cyclobenzaprine (TNX-102 SL) for Fibromyalgia: Efficacy and Safety in Two Randomized, Placebo-Controlled Trials

March 2025

UT Southwestern Microbiology Department Seminar 2025: Resurrecting Dr. Edward Jenner’s 1796 Horsepox Vaccine to Protect Against Mpox and Smallpox

March 2025

Controversies in Fibromyalgia 2025: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Treatment of Fibromyalgia at Bedtime to Target Non-Restorative Sleep Showed Durable Pain Reduction in Two Double-Blind Randomized Phase 3 Studies

November 2024

American College of Pheumatology Convergence 2024: Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia

October 2024

World Vaccine Congress: TNX-801 MPOX — A live, attenuated, minimally replicative, MPOX vaccine candidate

September 2024

Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024: The Importance of in Vitro Discriminatory Tests in the Development of a Sublingual Dosage Form of TNX-102 SL (Cyclobenzaprine HCI) Tablets

September 2024

Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024: Pharmacokinetic Properties of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine Hydrochloride

September 2024

Symposium to Honor Prof. David Evans: Using Synthetic Biology to Battle Mpox

August 2024

MHSRS 2024: Integrating Automated High-Throughput Scratch Assay and Cell Painting for Comprehensive Analysis of Cell Migration and Wound Healing

August 2024

MHSRS 2024: Two Clinical Trials of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder (PTSD) Provide Rationale to Study TNX-102 SL in the Aftermath of Trauma to Reduce Acute Stress Disorder (ASD) and Prevent PTSD

August 2024

MHSRS 2024: Development of the AURORA Platform Trial Network to Test Interventions to Reduce Acute Stress Reaction Symptoms, and Illustration of Use Testing Sublingual Cyclobenzaprine TNX-102 SL

August 2024

MHSRS 2024: TNX-102 SL for Fibromyalgia

August 2024

IASP 2024: Targeting Fibromyalgia Non-Restorative Sleep with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl): Results of the Positive Phase 3 RESILIENT Trial Consistent with Syndromal Improvement

June 2024

Vaccine Congress 2024: Horsepox: A Live Virus, Single-Dose Vaccine Platform

June 2024

AHS 2024: American Headache Society Consensus Statement and Other Recommendations: How Many Practitioners Comply With the Recommendations?

June 2024

EULAR 2024: Targeting Non-Restorative Sleep in Fibromyalgia with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) Significantly Improves Pain in RESILIENT, a Confirmatory Phase 3 Randomized Clinical Trial

June 2024

American Transplant Congress 2024: Combined blockade of CD154 and CD28 co-stimulation pathways attenuates pathogenic alloimmunityand prolongs survival in cynomolgus cardiac allografts

June 2024

ATC 2024: Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade –Based Immunosuppression

June 2024

ATC 2024: Delayed Immune Tolerance for Cardiac Allografts in Nonhuman Primates by Targeting CD154, CD2, and CD28 Costimulation Pathways

June 2024

ASCP Annual Meeting 2024: Effects of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) on Mood and Anxiety Symptoms in Fibromyalgia

May 2024

ASCP Annual Meeting 2024: Fibromyalgia-Type Long COVID

May 2024

ASCP Annual Meeting 2024: Acute Stress Disorder

April 2024

AACR Annual Meeting 2024: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

April 2024

World Vaccine Congress 2024: Attenuation of the Horsepox Virus Platform as a Vaccine for Mpox/Smallpox (TNX-801)

March 2024

American Chemistry Society (ACS) Spring 2024: Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations

March 2024

Controversies in Fibromyalgia 2024: Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled RESILIENT Trial

March 2024

Controversies in Fibromyalgia: Tonmya* (TNX-102 SL) in Development for the Management of Fibromyalgia

October 2023

 Pilot Evaluation of a Clinical Xeno Heart Transplant Regimen in a Preclinical Model

October 2023

Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade–Based Immunosuppression

October 2023

WVC Europe: A Novel Mpox Vaccine (Horsepox Platform) to Enhance Preparedness and Global Vaccine Equity

October 2023

FPWR: A planned phase 2, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of TNX-2900 for the treatment of patients with Prader-Willi syndrome

September 2023

CICON: mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated CT26.WT Subcutaneous and CT26-Luciferase Orthotopic Syngeneic Colorectal Cancer Models by Targeting MDSCs in BALB/C Mice

September 2023

IHC: Human Trigeminal Ganglia Possess Oxytocin Receptors on CGRP Positive Neurons, the Expression of which is Dramatically Increased by Inflammation

September 2023

IHC: Human Trigeminal Ganglia Possess Oxytocin Receptors on CGRP Positive Neurons: Expression Increased by Inflammation

June 2023

ATC: aCD154mAb (TNX-1500) Alone, or in Combination with Rapamycin, MMF, or aCD28mAb (VEL-101) Prolongs Cynomolgus Cardiac Allograft Survival

June 2023

ATC: Fc-Modified Anti-CD154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic Complications

June 2023

ATC: Efficacy of CD154 Blockade with TNX-1500 to Prevent Heart Allograft Immune Injury

June 2023

ASCP 2023: A Randomized Placebo-Controlled Multicenter Trial of Monotherapy with TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for Treatment of Major Depressive Disorder (MDD)

April 2023

AACR: MDSC-targeted TFF2-MSA Synergizes with PD-1 Blockade Therapy in Advanced Gastric Cancer Models

April 2023

AACR: MDSC-Targeted mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated MC38 and CT26.wt Murine Colorectal Cancer Models

April 2023

TNX-801: A Novel Mpox Vaccine: Live, Replicating, Attenuated Orthopoxvirus (Horsepox) Vaccine

April 2023

The Development of Horsepox Virus as a Vaccine Platform: Evaluation of TNX-1800 as a SARS-CoV-2 Vaccine

March 2023

The 5th International Congress on Controversies in Fibromyalgia

March 2023

Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Randomized, Placebo-Controlled RELIEF Trial

March 2023

TNX-2900 — Rare Disease Summit, Philadelphia, 23-March-2023

March 2023

mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in an Anti-PD-1 Treated MC38 Colorectal Cancer Model by Targeting MDSCs

February 2023

TNXP Presentation for BIO and Solve ME Event

January 2023

Primary vs Secondary Sex Hormones and Migraine

January 2023

Targeting the Wnt/β-catenin pathway as a broad-spectrum antiviral strategy

December 2022

Live Virus Smallpox and Monkeypox Vaccine

November 2022

Platform for Generating Fully Human anti-SARS-CoV-2 Spike Therapeutic Monoclonal Antibodies

November 2022

In Vitro Impact of Oxytocin on Human Sensory Neurons

September 2022

Retrospective Observational Database Study of Patients with Long COVID with Multi-Site Pain, Fatigue, and Insomnia: A Real-World Analysis of Symptomatology and Opioid Use

September 2022

Monotherapy with TNX-1500, an Fc-modified Anti-CD154 mAb, Prolongs Cardiac Allograft Survival in Cynomolgus Monkeys

September 2022

Long-term (>1 year) Rejection/TMA Free Survival of Kidney Xenografts with Triple Xenoantigen Knockout and Multiple Human Transgenes in Nonhuman Primates

September 2022

Long-term Rejection Free Renal Allograft Survival with Fc-modified Anti-CD154 Antibody Monotherapy in Nonhuman Primates

June 2022

TNX-1500, an Fc-modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival 

June 2022

Long Term Rejection Free Renal Allograft Survival with Fc Modified Anti CD154 Antibody Monotherapy in Nonhuman Primates

June 2022

Novel Targetable Pathways in Costimulation Pathway Blockade

June 2022

The Virus-host Interface: A Treasure Trove of Novel Antiviral Targets

June 2022

Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox